Sulfur Or Halogen Containing Patents (Class 536/122)
-
Patent number: 6943248Abstract: A crystalline form of sucralose, and a method of making it. The method involves continuously crystallizing sucralose from an aqueous solution by a process providing continuous removal and recirculation of the vessel contents, and providing a long residence time for sucralose in the system. The crystals thus formed are of a relatively low length/diameter ratio, have an unsymmetrical shape, and exhibit good stability. The larger crystals in particular are tapered as compared to the rod-like larger crystals in prior art product.Type: GrantFiled: April 30, 2003Date of Patent: September 13, 2005Assignee: Tate & Lyle Public Limited CompanyInventors: Steven J. Catani, Carolyn M. Merkel, Nicholas M. Vernon
-
Patent number: 6927209Abstract: The present invention relates to novel compounds of formula (I): in which: R1, R2 and R3, which are identical or different, are each independently: a (C1-C6)alkyl group, a pyridinyl group or a group —CH2—NR4R5, in which R4 and R5 are each independently a hydrogen atom or a (C1-C4)alkyl group, or alternatively R4 and R5 form, with the nitrogen atom to which they are bonded, a pyrrolidinyl, piperidinyl, hexahydroazepinyl, morpholinyl or piperazinyl group, with the proviso that at least one of the substituents R1, R2 and R3 is other than a (C1-C6)alkyl group, and their salts, solvates and hydrates, especially those which are pharmaceutically acceptable. These compounds are useful particularly for the treatment of disorders of the venous circulation.Type: GrantFiled: May 6, 2002Date of Patent: August 9, 2005Assignee: Laboratoires Fournier S.A.Inventors: Véronique Barberousse, Soth Samreth
-
Patent number: 6891035Abstract: Process for bulk autoclaving of polysaccharides, wherein the process includes: a) dissolving the polysaccharides in an aqueous solution and mixing until a homogeneous solution is obtained; b) filling the resulting solution in at least one container; c) placing the filled container(s) including the solution in an autoclave; d) placing a sensor in at least one of the containers; and e) autoclaving the filled containers.Type: GrantFiled: July 1, 2002Date of Patent: May 10, 2005Assignee: Biovitrum ABInventor: Olle Ljungquist
-
Patent number: 6875840Abstract: Disclosed are novel polymers derivatized with at least one —NOx group per 1200 atomic mass unit of the polymer. X is one or two. In one embodiment, the polymer is an S-nitrosylated polymer and is prepared by reacting a polythiolated polymer with a nitrosylating agent under conditions suitable for nitrosylating free thiol groups. The polymers of the present invention can be used to coat medical devices to deliver nitric oxide in vivo to treatment sites.Type: GrantFiled: September 23, 2003Date of Patent: April 5, 2005Assignee: Duke UniversityInventors: Jonathan S. Stamler, Eric J. Toone, Richard S. Stack
-
Patent number: 6844329Abstract: The present invention relates to novel synthetic polysaccharides with antithrombotic activity exhibiting at least one covalent bond with biotin or a biotin derivative and to a process employing avidin or streptavidin which makes it possible to neutralize these polysaccharides.Type: GrantFiled: September 20, 2001Date of Patent: January 18, 2005Assignee: Sanofi-SynthelaboInventors: Philippe Duchaussoy, Jean-Marc Herbert, Maurice Petitou, Pierre Savi
-
Patent number: 6828334Abstract: The present invention relates to pharmaceutical compositions containing fenofibrate in the form of an inclusion complex with cyclodextrin, having high dissolution profile and in vivo enhanced bioavailability as compared with plain micronized fenofibrate compositions. An inclusion complex has a molar ratio of fenofibrate (preferably in micronized form) to cyclodextrin of from about 1:0.5 to about 1:4, preferably from about 1:1 to about 1:2. The immediate release fenofibrate composition is preferably in the form of a tablet or in the form of granules inside a capsule.Type: GrantFiled: January 7, 2003Date of Patent: December 7, 2004Assignee: USV LimitedInventors: Suresh Kumar Gidwani, Purushottam Sharshikant Singnurkar
-
Patent number: 6812223Abstract: The present invention relates to novel crystalline glucosamine sulphate metal salts for use in the treatment of acute and chronic forms of rheumatic and arthritic diseases and of all the pathological conditions originating from metabolic disorders of the osteo-articular tissues. More particularly, the present invention relates to novel crystalline glucosamine sulphate metal salts having low metal content wherein the metal may be either sodium or potassium. The present invention further relates to a solution-based and a solvent-free process for the preparation of the novel crystalline glucosamine sulphate metal salts having low metal content and to pharmaceutical compositions comprising the novel crystalline glucosamine sulphate metal salts having low metal content.Type: GrantFiled: June 2, 2003Date of Patent: November 2, 2004Assignee: Nicholas Piramal India LimitedInventors: Triptikumar Mukhopadhyay, Ravi Gajanan Bhat, E. S. Sreekumar
-
Patent number: 6809198Abstract: The present invention provides an improved form of sucralose and a process for making it.Type: GrantFiled: August 1, 2003Date of Patent: October 26, 2004Assignee: Tate & Lyle Public Limited CompanyInventors: Fiesal El Kabbani, Amal Brohmi, Christian Heiss, Juan Navia, Steven J. Catani
-
Patent number: 6720419Abstract: A smaller molecule obtainable by allowing a sulfated fucan-digesting enzyme which digests a novel sulfated polysaccharide derived from an alga belonging to Laminariales to act on a sulfated fucan, and a method for producing the same.Type: GrantFiled: October 24, 2002Date of Patent: April 13, 2004Assignee: Takara Bio Inc.Inventors: Takeshi Sakai, Hitomi Amarume, Takashi Kawai, Kaoru Kojima, Kazuo Shimanaka, Katsushige Ikai, Ikunoshin Kato
-
Patent number: 6673891Abstract: Disclosed are novel polymers derivatized with at least one —SNO group per 1200 atomic mass unit of the polymer. In one embodiment, the S-nitrosylated polymer has stabilized —S-nitrosyl groups. In another embodiment the S-nitrosylated polymer prepared by polymerizing a compound represented by the following structural formula: R is an organic radical. Each X′ is an independently chosen aliphatic group or substituted aliphatic group. Preferably, each X′ is the same and is a C2-C6 alkylene group, more preferably —CH2—, —CH2CH2—, —CH2CH2CH2— or —CH2CH2CH2CH2—. p and m are independently a positive integer such that p+m is greater than two. The polymers of the present invention can be used to coat medical devices to deliver nitric oxide in vivo to treatment sites.Type: GrantFiled: June 5, 2002Date of Patent: January 6, 2004Assignee: Duke UniversityInventors: Jonathan S. Stamler, Eric J. Toone, Richard S. Stack
-
Patent number: 6670338Abstract: Pentasaccharides in acidic form and their pharmaceutically acceptable salts, the anionic form thereof having the formula: wherein: R represents hydrogen or an —SO3−, (C1-C3)alkyl or (C2-C3)acyl group; T represents hydrogen or an ethyl group; and n represents 1 or 2 for use in the treatment of pathologies associated with a clotting dysfunction.Type: GrantFiled: July 16, 2001Date of Patent: December 30, 2003Assignee: Sanofi-SynthelaboInventor: Maurice Petitou
-
Patent number: 6660722Abstract: Therapeutical method comprising administration to a patient of an effective amount of especially soluble laminarin for the treatment of tumors and more generally of cancers of the group comprising breast cancer, lung cancer, oesophagus cancer, stomach cancer, intestine and colon cancers, and for the treatment of viral, bacterial and fungal diseases as well as diseases related to immunostimulant deficiencies of human beings and warm-blood animals.Type: GrantFiled: November 30, 2001Date of Patent: December 9, 2003Assignee: Laboratoires Goemar S.A.Inventors: Jean-Claude Yvin, Vaclav Vetvicka
-
Patent number: 6656922Abstract: Polysaccharides, which are widely used as an anticoagulation drugs, especially heparin, are clinically administered only by intravenous or subcutaneous injection because of their strong hydrophilicity and high negative charge. Amphiphilic heparin derivatives were synthesized by conjugation to bile acids, sterols, and alkanoic acids, respectively. These heparin derivatives were slightly hydrophobic, exhibited good solubility in water, and have high anticoagulation activity. These slightly hydrophobic heparin derivatives are efficiently absorbed in the gastrointestinal tract and can be used in oral dosage forms. Methods of using these amphiphilic heparin derivatives and similarly modified macromolecules for oral administration are also disclosed.Type: GrantFiled: April 30, 2001Date of Patent: December 2, 2003Assignee: Mediplex Corporation, KoreaInventors: Youngro Byun, Yong-Kyu Lee
-
Patent number: 6642366Abstract: A process for manufacturing morphine-6-glucuronide and related compounds of the general structure of Formula 1: wherein optionally substituted morphine is conjugated with an optionally substituted member of a new class of intermediates, namely, 1-haloglucuronate esters, in the presence of iodine or an iodinium compound. The conjugation may be followed by conversion of R1 of Formula 1 into hydrogen and/or the removal of the ester groups from the glucuronic residue at R2 of Formula 1.Type: GrantFiled: June 7, 2002Date of Patent: November 4, 2003Assignee: UFC LimitedInventors: Feodor Scheinmann, Andrew Valentine Stachulski, John Ferguson, Jane Louise Law
-
Patent number: 6638916Abstract: A method for the inhibition of vascular smooth muscle cell hyperplasia in a human or other warm-blooded animal patient in need of such treatment, comprises administration to the patient of an effective amount of at least one sulfated oligosaccharide, wherein the oligosaccharide has the general formula I: R1—(Rx)n—R2 (I) wherein R1 and R2 and each Rx represents a monosaccharide unit, all of which may be the same or different, adjacent monosaccharide units being linked by 1→2, 1→3, 1→4 and/or 1→6 glycosidic bonds and n is an integer of from 1 to 6.Type: GrantFiled: May 9, 2000Date of Patent: October 28, 2003Assignee: The Australian National UniversityInventors: William B. Cowden, Douglas J. Francis, Christopher R. Parish
-
Patent number: 6627744Abstract: The present invention relates to a chemically modified mutant protein including a cysteine residue substituted for a residue other than cysteine n a precursor protein, the substituted cysteine residue being subsequently modified by reacting the cysteine residue with a glycosylated thiosulfonate. Also a method of producing the chemically modified mutant protein is provided. The present invention also relates to a glycosylated methanethiosulfonate. Another aspect of the present invention is a method of modifying the functional characteristics of a protein including providing a protein and reacting the protein with a glycosylated methanethiosulfonate reagent under conditions effective to produce a glycoprotein with altered functional characteristics as compared to the protein. In addition, the present invention relates to methods of determining the structure-function relationships of chemically modified mutant proteins.Type: GrantFiled: April 2, 2001Date of Patent: September 30, 2003Assignee: Genencor International, Inc.Inventors: Benjamin G. Davis, John Bryan Jones, Richard R. Bott
-
Patent number: 6627751Abstract: A hydrophobically modified anionic cellulose ether obtainable by a process comprising reacting an alkali metal cellulose with at least three alkylating reagents A, B, and C. Reagent A is selected from the group of haloacetic acids, alkali metal haloacetates, alkali metal vinyl sulfonates, and vinyl sulfonic acid. Reagent B has the formula R1—(OCH2CH(R2))n—P, wherein R1 represents a C2-C7 group, R2 is hydrogen or a methyl group, n is 0-2, and P represents a glycidyl ether group, a 3-halo-2-hydroxypropyl ether group, a 1,2-epoxy group, or a halide, and reagent C has the formula R3—(OCH2CH(R2))m—P, wherein R3 represents a C8-C30 group, m is 0-10, and R2 and P have the meaning as described above.Type: GrantFiled: December 6, 1999Date of Patent: September 30, 2003Assignee: Akko Nobel N.V.Inventors: Jan Gerardus Batelaan, Berend Jan Dijk, Peter Marten Van Der Horst
-
Patent number: 6589943Abstract: Formulations for enhanced mucosal absorption of heparin are disclosed. In one embodiment, a powdered heparin composition is made by dissolving an amphiphilic heparin derivative including heparin covalently bonded to a hydrophobic agent in a water phase, dispersing the water phase in an organic phase such that an emulsion is formed, and drying the emulsion. In another embodiment, an amorphiphilic heparin derivative dispersed in an oil phase is made by dissolving the amphiphilic heparin derivative in water or a water/organic co-solvent, dispersing the water or co-solvent in the oil phase, and evaporating the water or co-solvent. In another embodiment, heparin-containing nanoparticles having surfactant molecules associated with a hydrophobic agent on the outside of the nanoparticles are made by dissolving the amphiphilic heparin derivative in an aqueous solvent, mixing the surfactant with the aqueous solvent, and disrupting nanoparticles of the amphiphilic heparin derivative.Type: GrantFiled: May 9, 2001Date of Patent: July 8, 2003Assignee: Mediplex Corporation, KoreaInventors: Youngro Byun, Yong-Kyu Lee
-
Publication number: 20030066523Abstract: A sugar/additive blend useful as a binder or impregnant for carbon products. Simple sugars as well as sucrose are combined either in solution or in solid form with reactive additives such as ammonium hydrogen phosphate, ammonium chloride and para-toluene sulfuric acid. The sugar/additive blends form more and denser carbon residue than sugar alone when subjected to pyrolysis.Type: ApplicationFiled: June 28, 2002Publication date: April 10, 2003Applicant: UCAR Carbon Company Inc.Inventors: Irwin Charles Lewis, Terrence Anthony Pirro
-
Patent number: 6528497Abstract: Novel synthetic polysaccharides for use in the treatment of pathologies associated with a coagulation dysfunction.Type: GrantFiled: September 5, 2000Date of Patent: March 4, 2003Assignees: Sanofi-Synthelabo, Akzo Nobel N.V.Inventors: Johannes Basten, Cornelia Dreef-Tromp, Pierre Alexandre Driguez, Philippe Duchaussoy, Jean Marc Herbert, Maurice Petitou, Constant Van Boeckel
-
Patent number: 6495678Abstract: An immunosuppressant comprising Glucopyranose derivatives of the formula (I): wherein R is H, OH etc; G is —CH2CH(R1—R2)(R3—R4), in which R1 is a single bond, OCO-alkyl; R2, R4 is H, phenyl which may be substituted by halogen atoms etc.; R3 is alkylene; R5 is OCO-alkyl, R6 is H, phenyl which may be substituted by halogen atoms etc. or R5—R6 is OCO—Z-(dialkoxyphenyl); R7 is H, CH2OH etc; or non-toxic salts thereof as active ingredient. Glucopyranose derivatives of the formula (I) or non-toxic salts thereof possess an activity of immunosuppression, and being useful as the prevention and/or treatment of diseases caused by abnormal enhancement of immunity, e.g. allergic diseases, autoimmune diseases.Type: GrantFiled: November 6, 2000Date of Patent: December 17, 2002Assignee: Ono Pharmaceutical Co., Ltd.Inventors: Gen-ichiro Soma, Nagashige Omawari
-
Patent number: 6462191Abstract: A process for deoxofluorinating a C2-hydroxyl group of a furanose, includes: (a) mixing the furanose and a deoxofluorinating agent in a solvent to form a reaction mixture, and (b) heating the reaction mixture to greater than about 50° C. The process provides deoxofluorinated products, such as 2-fluoro-arabinoses, in yields of at least 80% of theoretical.Type: GrantFiled: July 13, 2000Date of Patent: October 8, 2002Assignee: Air Products and Chemicals, Inc.Inventor: Gauri Sankar Lal
-
Patent number: 6462215Abstract: A process that can be used for sulfonating, sulfating, or sulfamating an organic compound is disclosed. The process can comprise, consist essentially of, or consist of, contacting the organic compound with sulfur trioxide under a condition sufficient to effect the sulfonation, sulfation, or sulfamation of the organic compound. The organic compound can be an aromatic compound, alcohol, carbohydrate, amine, amide, protein, or combinations of two or more thereof. The sulfur trioxide can be present in a complex comprising an inorganic support such as zeolite, silicalite, silica, titanosilicate, borosilicate, clay, aluminophosphate, and combinations of two or more thereof.Type: GrantFiled: February 4, 2002Date of Patent: October 8, 2002Assignee: E. I. du Pont de Nemours and CompanyInventors: Stephen Ernest Jacobson, David Richard Corbin
-
Patent number: 6407072Abstract: Novel N-acyl-lysogangliosides obtained from gangliosides by deacyation of the ceramide group, wherein the acyl group is derived from an aliphatic acid having from 2 to 24 carbon atoms, substituted by one or more polar groups. The N-acyl-lysogangliosides of the invention exhibit an inhibiting action on protein-kinase C activation and, thus, can be utilized in therapies for various pathologies of the nervous system.Type: GrantFiled: June 30, 1994Date of Patent: June 18, 2002Assignee: Fidia S.p.A.Inventors: Francesco Della Valle, Aurelio Romeo
-
Patent number: 6403759Abstract: Disclosed are novel polymers derivatized with at least one —SNO group per 1200 atomic mass unit of the polymer. In one embodiment, the S-nitrosylated polymer has stabilized-S-nitrosyl groups. In another embodiment the S-nitrosylated polymer prepared by polymerizing a compound represented by the following structural formula: R is an organic radical. Each X′ is an independently chosen aliphatic group or substituted aliphatic group. Preferably, each X′ is the same and is a C2-C6 alkylene group, more preferably—CH2—, —CH2CH2—, —CH2CH2CH2— or —CH2CH2CH2CH2—. p and m are independently a positive integer such that p+m is greater than two. The polymers of the present invention can be used to coat medical devices to deliver nitric oxide in vivo to treatment sites.Type: GrantFiled: December 29, 2000Date of Patent: June 11, 2002Assignee: Duke UniversityInventors: Jonathan S. Stamler, Eric J. Toone, Richard S. Stack
-
Patent number: 6391862Abstract: A cyclodextrin composition of substantially pure, sulfated-cyclodextrin derivatives particularly suitable as chiral resolving agents for enantioseparation by electrophoresis. The cyclodextrin composition preferably have an isomeric purity of at least 80 mole %. Non-sulfato substituents for the substantially pure cyclodextrin derivatives are hydrogen, C1-C12 alkyl groups, C2-C8 hydroxyalkyl groups, C1-C12 alkylnitryl groups, C2-C12 acyl groups, aryl groups, carbamate groups, thiocarbamate groups or combinations thereof.Type: GrantFiled: October 14, 1998Date of Patent: May 21, 2002Assignee: The Texas A&M University SystemInventor: Gyula Vigh
-
Patent number: 6388060Abstract: This present invention provides methods of sulfating uronic acid-containing polysaccharides. High levels of sulfation can be obtained using the methods of the present invention.Type: GrantFiled: November 4, 1999Date of Patent: May 14, 2002Assignee: Vascular Therapeutics Inc.Inventors: Steven Y. C. Guo, Edward H. Conrad
-
Patent number: 6355784Abstract: The present invention discloses new and novel halogenated anthracyclines linked through the saccharide portions. These congeners show high activity in vitro against several tumor cell lines. In doxorubicin (DOX) sensitive cell lines, they are at least as cytotoxic as DOX and in some cases more so. Many of these 4′- and 6′-fluorinated anthracyclines are more effective against multidrug-resistant tumors than was DOX, and/or have greater effectiveness than DOX against DOX sensitive cells. The compounds of this invention also have anti-amyloidogenic effects and the use of these compounds in the treatment of Alzheimer's disease is contemplated.Type: GrantFiled: June 10, 1999Date of Patent: March 12, 2002Inventors: Waldemar Priebe, Marta Krawczyk, Piotr Skibicki, Izabela Fokt, Krzysztof Dziewiszek, Grzegorz Grynkiewicz, Roman Perez-Soler
-
Patent number: 6288043Abstract: An injectable composition is provided for promoting bone and/or cartilage growth comprising hyaluronic acid cross-linked to sulfated polysaccharide through linking groups. The linking groups are diamines or amino polyalkylene glycols. The sulfated polysaccharide binds growth factors suitable for promoting tissue growth at the site of application of the composition.Type: GrantFiled: June 18, 1999Date of Patent: September 11, 2001Assignee: Orquest, Inc.Inventors: Robert C. Spiro, LinShu Liu
-
Patent number: 6245753Abstract: Polysaccharides, which are widely used as an anticoagulation drugs, especially heparin, are clinically administered only by intravenous or subcutaneous injection because of their strong hydrophilicity and high negative charge. Amphiphilic heparin derivatives were synthesized by conjugate to bile acids, sterols, and alkanoic acids, respectively. The hydrophobicity of the heparin derivatives depended on the feed mole ratio of heparin to hydrophobic agent. The heparin derivatives were slightly hydrophobic and exhibited good solubility in a water-acetone solvent, as well as water. The heparin derivatives have a high anticoagulant activity. These slightly hydrophobic heparin derivatives can be absorbed in gastric intestinal tract and can be used as oral dosage form. Also, the heparin derivatives can be used for the surface modification to prevent anticoagulation for medical devices such as extracorporeal devices and implanted devices.Type: GrantFiled: April 27, 1999Date of Patent: June 12, 2001Assignee: Mediplex Corporation, KoreaInventors: Youngro Byun, Yong-Kyu Lee
-
Patent number: 6232434Abstract: Disclosed are novel polymers derivatized with at least one —SNO group per 1200 atomic mass unit of the polymer. In one embodiment, the S-nitrosylated polymer has stabilized —S-nitrosyl groups. In another embodiment the S-nitrosylated polymer prepared by polymerizing a compound represented by the following structural formula: R is an organic radical. Each X′ is an independently chosen aliphatic group or substituted aliphatic group. Preferably, each X′ is the same and is a C2-C6 alkylene group, more preferably —CH2—, —CH2CH2—, —CH2CH2CH2— or —CH2CH2CH2CH2—. p and m are independently a positive integer such that p+m is greater than two. The polymers of the present invention can be used to coat medical devices to deliver nitric oxide in vivo to treatment sites.Type: GrantFiled: June 23, 1998Date of Patent: May 15, 2001Assignee: Duke University Medical CenterInventors: Jonathan S. Stamler, Eric J. Toone, Richard S. Stack
-
Patent number: 6229008Abstract: &agr;-D-pentofuranoside derivatives have the general formula (D), in which R stands for (C1-C4)alkyl that is non-substituted or substituted one or several times by halogen, (C1-C4)alkyl, (C1-C4)alkoxy and/or phenyl, and R1 stands for [(C6-C20)aryl]k−[(C1-C4)alkyl or [(C6-C20)]aryl]k−[(C1-C12)alkyl)(3-k)Si in which k=0 to 3, that are non-substituted or substituted one or several times by halogen, (C1-C4)alkyl, (C1-C4)alkoxy and/or (C6-C20) aryl, or preferably a benzyl that is non-substituted or substituted one or several times by the above substituents. Also disclosed are starting and intermediary compounds, up to furanosides (D) having an analogous structure, processes for preparing said furanosides and their precursors, and their use.Type: GrantFiled: April 18, 1997Date of Patent: May 8, 2001Inventors: Jörn Saischek, Berndt Stadelmann
-
Patent number: 6228998Abstract: A glycosaminoglycan derivative is disclosed wherein a first amino group of a spacer compound (NH2—Y—NH2) is bonded to an aldehyde formed by reducing and partially oxidizing a reducing end sugar of a glycosaminoglycan, via an aminoalkyl bond, or a lactone formed by oxidizing and cyclodehydrating the reducing end sugar of a glycosaminoglycan, via an acid amide bond, and further a hydrocarbon compound having a allyl group at one end and a functional group at another end which is bonded to the second amino group of the spacer compound. This derivative is useful as a substrate in a process for identifying a glycosaminoglycan-degrading enzyme that gives good reproducibility and sensitivity.Type: GrantFiled: July 20, 1995Date of Patent: May 8, 2001Assignee: Seikagaku Kogyo Kabushiki KaishaInventors: Ryu Miura, Sadako Yamagata, Tatsuya Yamagata
-
Patent number: 6225450Abstract: The invention describes a new method to sequence DNA. The improvements over the existing DNA sequencing technologies are high speed, high throughput, no electrophoresis and gel reading artifacts due to the complete absence of an electrophoretic step, and no costly reagents involving various substitutions with stable isotopes. The invention utilizes the Sanger sequencing strategy and assembles the sequence information by analysis of the nested fragments obtained by base-specific chain termination via their different molecular masses using mass spectrometry, as for example, MALDI or ES mass spectrometry. A flirter increase in throughput can be obtained by introducing mass-modifications in the oligonucleotide primer, chain-terminating nucleoside triphosphates and/or in the chain-elongating nucleoside triphosphates, as well as using integrated tag sequences which allow multiplexing by hybridization tag specific probes with mass differentiated molecular weights.Type: GrantFiled: June 7, 1995Date of Patent: May 1, 2001Assignee: Sequenom, Inc.Inventor: Hubert Köster
-
Patent number: 6207652Abstract: Apoptosis inducers, anticancer drugs and carcinostatic drugs containing sulfated-fucose-containing polysaccharide(s) and/or degradation product(s) thereof, and a method for inducing apoptosis by using sulfated-fucose-containing polysaccharide(s) and/or degradation product(s) thereof as the active ingredient. A degrading enzyme which is useful in the production of the degradation products of sulfated-fucose-containing polysaccharides.Type: GrantFiled: April 9, 1998Date of Patent: March 27, 2001Assignees: Takara Shuzo Co., Ltd., Research Institute for GlycotechnologyInventors: Takeshi Sakai, Hideo Kitano, Fu-Gong Yu, Shinji Nakayama, Kaoru Kojima, Hitomi Kimura, Yoshikuni Nakanishi, Kaoru Katayama, Takanari Tominaga, Kazuo Shimanaka, Katsushige Ikai, Ikunoshin Kato
-
Patent number: 6190637Abstract: The present invention provides a method for preparing [F-18]-fluoride ion which comprises the step of bringing [O-18]-enriched water containing [F-18]-fluoride ion formed by proton irradiation of [O-18]-enriched water into contact with a strongly acidic cation exchange resin to remove impurity cations, the step of then bringing the [O-18]-enriched water containing [F-18]-fluoride ion treated above into contact with a weakly basic anion exchange resin to make [F-18]-fluoride ion adsorbed to the resin and, along therewith, to recover the [O-18]-enriched water which has passed through the resin, and the step of eluting and collecting the [F-18]-fluoride ion adsorbed to the weakly basic anion exchange resin.Type: GrantFiled: March 11, 1999Date of Patent: February 20, 2001Assignee: Nihon Medi-Physics Co., Ltd.Inventors: Sento Ino, Masahiko Tamura, Osamu Itoh
-
Patent number: 6184365Abstract: 7-O-(4-Amino-2,4,6-trideoxy-2-fluoro-&agr;-L-talopyranosyl)-daunomycinone or -adriamycinone is now synthesized as a novel daunomycinone or adriamycinone derivative having the general formula wherein R is a hydrogen atom or hydroxyl group. These novel compounds according to this invention exhibit excellent antitumor activities and have a high solubility in water, and hence they are useful as an antitumor agent.Type: GrantFiled: December 16, 1997Date of Patent: February 6, 2001Assignee: Zaidan Hojin Biseibutsu Kagaku Kenkyu KaiInventors: Tomio Takeuchi, Sumio Umezawa, Tsutomu Tsuchiya, Yasushi Takagi
-
Patent number: 6184196Abstract: The invention relates to the synthesis of sulfonated sucrose compounds, surfactants and intermediate cyclic sulfates.Type: GrantFiled: May 27, 1999Date of Patent: February 6, 2001Assignee: University of Iowa Research FoundationInventors: Helene G. Bazin, Tulay Polat, Robert J. Linhardt
-
Patent number: 6177553Abstract: Solid phase synthetic methods of forming sulfur-linked disaccharides and oligosaccharides are described, wherein a saccharide or oligosaccharide bearing a protected thiol-group at the anomeric carbon is immobilized onto a solid support at any position other than the anomeric carbon atom of the reducing sugar. The resultant immobilized thiol, or a derivative thereof, undergoes nuclcophilic saccharide addition to provide a di- or oligosaccharide.Type: GrantFiled: August 7, 1998Date of Patent: January 23, 2001Assignee: Synsorb Biotech, Inc.Inventors: Ole Hindsgaul, Gerd Hummel
-
Patent number: 6174863Abstract: The invention relates to a carbohydrate derivative having formula I wherein R1 is (1-4C)alkoxy; R2, R3 and R4 are independently (1-4C)alkoxy or OSO3−, the total number of sulfate groups is 4, 5, or 6; and the twisted lines represent bonds either above or below the plane of the six-membered ring to which they are attached; or a pharmaceutically acceptable salt thereof. The compounds of the invention have antithrombotic activity and may be used for treating or preventing thrombosis and for inhibiting smooth muscle cell proliferation.Type: GrantFiled: November 18, 1998Date of Patent: January 16, 2001Assignee: Akzo Nobel N.V.Inventors: Constant Adriaan Anton van Boeckel, Maurice Petitou, Philippe Duchaussoy, Cornelia Maria Dreef-Tromp, Johannes Egbertus Maria Basten
-
Patent number: 6172207Abstract: A process and a device for synthesizing labeled compounds. The process involves preparing a labeling agent, labeling a precursor with the labeling agent, where the precursor is a protected substrate, and deprotecting the labeled precursor to convert the labeled precursor to a labeled compound by passing the labeled precursor through a solid support in a column or a cartridge. The process may be used to convert labeled tetraacetylfluoroglucose (TAFg) to labeled fluoro-deoxy-glucose (FDG) for use in nuclear medical imaging. The process is more rapid than conventional methods and is performed at room temperature rather than high temperature for conventional technology.Type: GrantFiled: July 29, 1998Date of Patent: January 9, 2001Assignees: Coincidence S. A., Universite Libre de Bruxelles, Universite de LiegeInventors: Philippe E. Damhaut, Michel Monclus, John J. Van Namen, Eric Mulleneers, Jean-Luc E. Morelle, Christian F. Lemaire, Andre Luxen, Benjamin P. Lauricella
-
Adsorbent carrier containing immobilized sulfated polysaccharide and ligand for direct hemoperfusion
Patent number: 6156492Abstract: An adsorbent for use in direct hemoperfusion to adsorb and remove harmful substances from blood is prepared by immobilizing a sulfated polysaccharide and/or its salt on a water-insoluble carrier. Preferably, the sulfated polysaccharide has a limiting viscosity of 0.005 to 0.5 dl/g and a sulfur content of 5 to 22% by weight, and is immobilized on the carrier in an amount of 0.02 to 200 mg per ml of carrier. Carrier particles can have an average particle size of 30 to 5000 .mu.m, and preferably 120 to 800 .mu.m. The sulfated polysaccharide inhibits adhesion of hemocytes and exhibits an anticoagulation property to extend blood coagulation time, and has additional functions of adsorbing releasing factors released from hemocytes, adsorbing lipoproteins, and enabling reduction of carrier particle size to about 30 .mu.m. Immobilizing a ligand on the carrier with the sulfated polysaccharide makes it possible to adsorb and remove specific substances in blood that bind to the ligand.Type: GrantFiled: December 18, 1998Date of Patent: December 5, 2000Assignee: Kaneka CorporationInventors: Akira Kobayashi, Satoshi Takata -
Patent number: 6139751Abstract: Heavy metals can be effectively complexed with a derivative of a fructan, which derivative contains complexing groups chosen from --X--CY--ZM, --X--CY--ZM, --X--CY--S--S--CY--X--Q, --PY'(--Z'M).sub.2, --SO.sub.3 M and --NR--CH.sub.2 --COOM, where M is a metal or hydrogen, Q denotes the residue of an alcohol or polyol, R is hydrogen or carboxymethyl and X, Y, Y', Z and Z', independently of one another, are O, S or NH and at least one of X, Y and Z is S, with a degree of substitution of 0.1-2.5. The complexing groups are in particular xanthate, xanthide or dithiocarbamate groups.Type: GrantFiled: January 14, 1999Date of Patent: October 31, 2000Assignee: Cooperatie Cosun U.A.Inventors: Piet Marc Paul Bogaert, Theodoor Maximiliaan Slaghek, Henricus Wilhelmus Carolina Raaijmakers
-
Patent number: 6075013Abstract: The present invention provides compositions and methods for the treatment of cardiovascular diseases. More particularly, the present invention relates to modifying thrombus formation by administering an agent which, inter alia, is capable of (1) inactivating fluid-phase thrombin and thrombin which is bound either to fibrin in a clot or to some other surface by catalyzing antithrombin; and (2) inhibiting thrombin generation by catalyzing factor Xa inactivation by antithrombin III (ATIII). The compositions and methods of the present invention are particularly usefull for preventing thrombosis in the circuit of cardiac bypass apparatus and in patients undergoing renal dialysis, and for treating patients suffering from or at risk of suffering from thrombus-related cardiovascular conditions, such as unstable angina, acute myocardial infarction (heart attack), cerebrovascular accidents (stroke), pulmonary embolism, deep vein thrombosis, arterial thrombosis, etc.Type: GrantFiled: June 5, 1998Date of Patent: June 13, 2000Assignee: Hamilton Civic Hospitals Research Development Inc.Inventors: Jeffrey I. Weitz, Jack Hirsh
-
Patent number: 6068697Abstract: A polysaccharide derivative prepared by replacing all or part of the hydroxyl hydrogen atoms of a polysaccharide or polysaccharide derivative by (A) a hydrophobic substituent having a C.sub.8 -C.sub.43 hydrocarbon chain as the partial structure and (B) an ionic hydrophilic substituent having at least one member selected from the group consisting of sulfonic, carboxyl phosphoric, and sulfate groups and salts thereof as the partial structure, wherein the average degree of replacement by the substituent (A) is 0.0001 or above but below 0.001 per constituent monosaccharide residue as determined by Zeisel's method or the diazomethane method and that by the substituent (B) is 0.01 to 2.0 per constituent monosaccharide residue as determined by colloidal titration. This polysaccharide derivative is useful as the admixture for hydraulic materials and can give stable hydraulic compositions excellent in dispersion.Type: GrantFiled: July 14, 1998Date of Patent: May 30, 2000Assignee: Kao CorporationInventors: Hotaka Yamamuro, Takeshi Ihara, Tomohito Kitsuki, Tetsuya Miyajima, Fujio Yamato, Makoto Kohama
-
Patent number: 6069238Abstract: An improved and a new synthetic route for the reparation of spirocyclic C-glycoside compounds having the following general structure are described. ##STR1## Novel derivatives of spirocyclic C-glycoside compounds are also disclosed which may be used as intermediates in the synthesis and evaluation of potential pharmaceutically active materials.Type: GrantFiled: June 28, 1999Date of Patent: May 30, 2000Assignee: Eli Lilly and CompanyInventors: Stephen Andrew Hitchcock, Chafiq Hamdouchi, Concepcion Sanchez-Martinez, Almudena Rubio Esteban
-
Patent number: 6063915Abstract: Carrageenan compostions comprising from about from about 79 mol % to about 95 mol % iota carrageenan and from about 0.1 mol % to about 10 mol % nu carrageenan, and carrageenan and compositions which exhibit elastic modulus, G'--1 Hz at 5.degree. C., of greater than about 200 Pa, elastic modulus, G'--1 Hz at 25.degree. C., of less than about 200 Pa, viscous modulus, G"--0.2 Hz at 5.degree. C., of from about 5 Pa to about 25 Pa, and melting point of less than 60.degree. C., in a 1.2 wt % aqueous gel, and methods of producing the same.Type: GrantFiled: July 30, 1998Date of Patent: May 16, 2000Assignee: Hercules IncorporatedInventors: Jack Harbo Hansen, Jan Groendal, Henrik Larsen
-
Patent number: 6054577Abstract: A novel endo-fucoidan-lyase and a novel microorganism useful in the production of sugar compounds. Sugar compounds represented by the following general formula (1), wherein at least one of alcoholic hydroxyl group has been sulfated, or salts thereof: ##STR1## wherein Y represents hydrogen or a group represented by the following formula (2).Type: GrantFiled: September 26, 1997Date of Patent: April 25, 2000Assignees: Takara Shuzo Co., Ltd., Research Institute For GlycotechnologyInventors: Takeshi Sakai, Hitomi Kimura, Kaoru Kojima, Katsushige Ikai, Sumiko Akiyoshi, Yoshikuni Nakanishi, Ikunoshin Kato
-
Patent number: 6037327Abstract: A pharmaceutical agent for treating an amyloid disease in a patient, wherein the pharmaceutical agent comprises a saccharide containing at least one substituted anionic group, or a pharmaceutically acceptable salt of the saccharide containing at least one substituted anionic group, and in preferred embodiments is a therapeutically effective amount of glucose pentasulfate. The agent is directed to amyloid diseases in general and to Alzheimer's disease in particular. The pharmaceutical agent may advantageously be combined with a pharmaceutically acceptable carrier, diluent or excipient.Type: GrantFiled: August 28, 1998Date of Patent: March 14, 2000Assignee: University of WashingtonInventors: Gerardo Castillo, Alan D. Snow
-
Patent number: 6028191Abstract: A method for obtaining sulphated polysaccharides using the free radical depolymerization of a fucan from Phaeophyceae in the presence of a metal catalyst and of hydrogen peroxide is described. The method of the invention provides polysaccharide fractions with a molecular weight of 10,000 g/mol or less, with anticoagulant properties.Type: GrantFiled: May 6, 1998Date of Patent: February 22, 2000Assignees: Centre National de la Recherche Scientifique (CNRS), Institut Francais de Recherche Pour L'Exploitation de la Mer (Ifremer)Inventors: Alain Nardella, Frederic Chaubet, Corinne Sinquin, Sylvia Colliec Jouault, Catherine Boisson-Vidal, Patrick Durand, Jacqueline Jozefonvicz